BACKGROUND: The present study was carried out to evaluate the blood pressure (BP)-lowering effect and the safety aspects of Lactobacillus helveticus LBK-16H fermented milk with high tripeptide doses on hypertensive subjects using 24-h ambulatory measurements (ABPM). METHODS: In a randomized, double blinded placebo-controlled parallel group study, 94 hypertensive patients not receiving any drug treatment were given150 mL twice daily of either L. helveticus LBK-16H fermented milk with a high concentration of tripeptides (Ile-Pro-Pro 7.5 mg/100 g and Val-Pro-Pro 10 mg/100 g) or a control product, for 10 weeks after a 4-week run-in period. Twenty-four-hour ABPM were taken at the beginning and at the end of the intervention period. The average baseline systolic and diastolic BP values were 132.6 +/- 9.9/83.0 +/- 8.0 mm Hg in the L. helveticus group and 130.3 +/- 9.6 /80.2 +/- 7.0 mm Hg in the control group. RESULTS: There was a mean difference of -4.1 +/- 0.9 mm Hg in systolic (P = .001) and a -1.8 +/- 0.7 mm Hg in diastolic BP (P = .048) between the L. helveticus group and the control group. There was no difference in the sum of the adverse events (P = .820). CONCLUSIONS: Lactobacillus helveticus LBK-16H fermented milk containing bioactive peptides, in daily use, does have a BP-lowering effect in hypertensive subjects and is thus a potential for the dietary treatment of hypertension.
RCT Entities:
BACKGROUND: The present study was carried out to evaluate the blood pressure (BP)-lowering effect and the safety aspects of Lactobacillus helveticus LBK-16H fermented milk with high tripeptide doses on hypertensive subjects using 24-h ambulatory measurements (ABPM). METHODS: In a randomized, double blinded placebo-controlled parallel group study, 94 hypertensivepatients not receiving any drug treatment were given 150 mL twice daily of either L. helveticus LBK-16H fermented milk with a high concentration of tripeptides (Ile-Pro-Pro 7.5 mg/100 g and Val-Pro-Pro 10 mg/100 g) or a control product, for 10 weeks after a 4-week run-in period. Twenty-four-hour ABPM were taken at the beginning and at the end of the intervention period. The average baseline systolic and diastolic BP values were 132.6 +/- 9.9/83.0 +/- 8.0 mm Hg in the L. helveticus group and 130.3 +/- 9.6 /80.2 +/- 7.0 mm Hg in the control group. RESULTS: There was a mean difference of -4.1 +/- 0.9 mm Hg in systolic (P = .001) and a -1.8 +/- 0.7 mm Hg in diastolic BP (P = .048) between the L. helveticus group and the control group. There was no difference in the sum of the adverse events (P = .820). CONCLUSIONS:Lactobacillus helveticus LBK-16H fermented milk containing bioactive peptides, in daily use, does have a BP-lowering effect in hypertensive subjects and is thus a potential for the dietary treatment of hypertension.
Authors: Niels Peter Möller; Katharina Elisabeth Scholz-Ahrens; Nils Roos; Jürgen Schrezenmeir Journal: Eur J Nutr Date: 2008-05-27 Impact factor: 5.614
Authors: Jasenka Zubcevic; Elaine M Richards; Tao Yang; Seungbum Kim; Colin Sumners; Carl J Pepine; Mohan K Raizada Journal: Circ Res Date: 2019-06-20 Impact factor: 17.367
Authors: T Jauhiainen; M Rönnback; H Vapaatalo; K Wuolle; H Kautiainen; P-H Groop; R Korpela Journal: Eur J Clin Nutr Date: 2010-02-10 Impact factor: 4.016
Authors: Tiina Jauhiainen; Taru Pilvi; Zhong Jian Cheng; Hannu Kautiainen; Dominik N Müller; Heikki Vapaatalo; Riitta Korpela; Eero Mervaala Journal: J Nutr Metab Date: 2009-11-30